Now Reading: Symbiotec Pharmalab to raise Rs 1,757 crore via IPO
-
01
Symbiotec Pharmalab to raise Rs 1,757 crore via IPO
Symbiotec Pharmalab, an Indore-based pharmaceutical and biotechnology company, will launch its initial public offering on Monday, August 25, to raise up to Rs 1,757 crore. The price band is set at Rs…
Symbiotec Pharmalab, an Indore-based pharmaceutical and biotechnology company, will launch its initial public offering on Monday, August 25, to raise up to Rs 1,757 crore. The price band is set at Rs 938-988 per share, valuing the company at about Rs 6,350 crore at the upper end. Bids can be placed for a minimum of 15 shares and in multiples thereafter.
The IPO combines a fresh issue of Rs 150 crore and an offer for sale of Rs 1,607 crore. Promoter Satwani Holdings LLP will sell shares worth Rs 144 crore, while investors Rosewood Investments and India Business Excellence Fund III will offload shares worth Rs 988 crore and Rs 475 crore, respectively. Proceeds from the fresh issue will be used for debt repayment and general corporate purposes.
The company claims global leadership in corticosteroid and steroidal-hormone active pharmaceutical ingredients by volume, with market shares of 38.2% and 23.8%. For the year ended March 2026, Symbiotec reported a net profit of Rs 110 crore, up 13.6% from Rs 97 crore, and revenue of Rs 869 crore, up 15.6%. The equity shares are scheduled to list on the BSE and NSE on September 1.
Indian Opinion Analysis
The IPO comes at a time when the domestic pharma sector is seeing heightened investor interest, buoyed by strong export demand and a focus on complex generics. Symbiotec's strength in corticosteroids, a high-barrier segment with few global players, gives it pricing power. The bulk of the issue is an offer for sale, meaning the company itself will not receive most of the proceeds. Investors will watch the debt reduction from the fresh issue, given that the company's borrowings stood at Rs 472 crore as of March 2026. The subscription figures and listing performance on September 1 will be the first real test of market appetite for a pure-play API and CDMO player.
Source: thehindubusinessline.com
This story was synthesised by AI from the source linked above.
